Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | PKLR | P30613 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 5/20 | 0.53 |
| ▸ | F13A1 | P00488 | 4/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | TGM1 | P22735 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1181678 | 0.86 | MEN1 (0.58) | PKMTGM2F13A1TGM1 | |
| SCHEMBL309243 | 0.85 | TGM2 (0.64) | CNR1GAAPKMTGM2F13A1 | |
| SCHEMBL7737635 | 0.84 | TGM2 (0.55) | PKMTGM2F13A1STSTGM1 | |
| SCHEMBL14696050 | 0.84 | GAA (0.55) | LMNAGAASMN1; SMN2HTTTGM2 | |
| SCHEMBL18701978 | 0.84 | LMNA (0.66) | LMNACNR1GAASMN1; SMN2HTT | |
| SCHEMBL18711333 | 0.84 | LMNA (0.69) | LMNACNR1GAASMN1; SMN2HTT | |
| SCHEMBL5424584 | 0.83 | PKLR (0.56) | PKMPKLRTGM2F13A1TGM1 | |
| SCHEMBL2378015 | 0.83 | TGM2 (0.54) | TGM2F13A1TGM1 | |
| SCHEMBL20408701 | 0.83 | SMN1; SMN2 (0.62) | LMNACNR1GAASMN1; SMN2HTT | |
| SCHEMBL15100856 | 0.83 | LMNA (0.61) | LMNACNR1GAASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116606292-A | Pyrido [1,2-a ] pyrimidinone derivatives containing sulfonamide unit, preparation method and application thereof | 贵州大学 | 2023-08-18 | — | — | CN | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | LMNA 577/4885CNR1 94/4885GAA 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.